HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EC’s SCCS Concurs With CIR On Methylene Glycol In Hair Straighteners

This article was originally published in The Rose Sheet

Executive Summary

Due to concerns about heated methylene glycol releasing formaldehyde into the air at levels above safe limits, EC’s Scientific Committee on Consumer Safety says the ingredient is unsafe for use in hair-straightening products.

You may also be interested in...



Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

Brazilian Blowout Sales May Be Squashed In California By Year-End

The California attorney general files a motion in Los Angeles Superior Court claiming Brazilian Blowout maker GIB LLC is not honoring the terms of a January 2012 consent judgment, which requires the firm to stop selling its products in California if they emit volatile organic compounds in excess of state limits. Testing from three laboratories shows the company’s products to be in violation, but GIB wants greater clarification.

House Hearing Probes FDA’s Cosmetics Role

Stakeholders from industry, government and FDA discussed ideas for changing the agency’s oversight of cosmetics at a House subcommittee meeting March 27. The need for a national regulatory system, mandatory recalls, company and ingredient registration and adverse event reporting were debated.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel